Monoclonal Antibodies and Antivirals against SARS-CoV-2 Reduce the Risk of Long COVID: A Retrospective Propensity Score-Matched Case–Control Study

Long COVID is a complex condition affecting quality of life, with limited therapeutic options. We investigated the occurrence of long COVID in subjects receiving early therapy with monoclonal antibodies (mAbs) or antivirals to reduce the risk of COVID-19 progression. In this retrospective study we e...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Antonio Cimellaro, Desirée Addesi, Michela Cavallo, Francesco Spagnolo, Edoardo Suraci, Raffaella Cordaro, Ines Spinelli, Francesco Passafaro, Manuela Colosimo, Medea Pintaudi, Carmelo Pintaudi, on behalf of the CATAnzaro LOng COVID (CATALOCO) Study Group
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	MDPI AG 2022-12-01
Ráidu:	Biomedicines
Fáttát:	long COVID post-COVID syndrome COVID-19 SARS-CoV-2 monoclonal antibodies antivirals
Liŋkkat:	https://www.mdpi.com/2227-9059/10/12/3135
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!